Native and Engineered Extracellular Vesicles for the Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
Zhengyan Gu, Wenjun Xue, Guanchao Mao, Zhipeng Pei, Jingjing Li, Mingxue Sun, Xinkang Zhang, Shanshan Zhang, Songling Li, Jinfeng Cen, Kai Xiao, Ying Lu, Qingqiang Xu
TL;DR
This paper reviews how natural and modified extracellular vesicles can be used to treat severe lung conditions like acute respiratory distress syndrome.
Contribution
The paper provides a comprehensive overview of engineering strategies to enhance extracellular vesicles for ALI/ARDS treatment.
Findings
Extracellular vesicles are biocompatible and do not trigger immune rejection, making them suitable for therapeutic use.
Engineering strategies can improve the clinical potential of extracellular vesicles for treating lung injuries.
The paper discusses challenges and opportunities in translating extracellular vesicle therapies to clinical settings.
Abstract
Extracellular vesicles (EVs) are lipid bilayer nanoparticles naturally released from cells, playing a crucial role in intercellular communication. They modulate gene expression and regulate physiological and pathological processes, including acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Research has shown that EVs contain a variety of active components, are biocompatible and small in size, and do not trigger immune rejection, making the infusion of exogenous EVs a promising therapeutic tool. With further research, engineering strategies have been proposed to enhance the clinical potential of EVs. These strategies involve modifying either donor cells that secrete EVs or the EVs themselves and can be engineered to circumvent the limitations of native EVs. In this review, an overview of the biological properties of native EVs is provided and the current…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsExtracellular vesicles in disease · Nanoplatforms for cancer theranostics · MicroRNA in disease regulation